Skip to main content

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Completed · Phase 1 · NCT04649385

Conditions: Advanced Solid Tumor

At a glance

Research payments reported, 2025
$344,907
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
157

About the trial

Sponsor
BeiGene
Tested
BGB-15025 (drug), Tislelizumab (drug), Carboplatin (drug), Cisplatin (drug), Pemetrexed (drug), Oxaliplatin (drug), Capecitabine (drug), Paclitaxel (drug), nab-paclitaxel (drug)
Dates
Started 2021-03-04; completion 2026-05-15
Results posted
Not yet

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

From ClinicalTrials.gov, last updated 2026-06-26. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines USA, Inc. reported $344,907 in research payments for this study in 2025 (36 payments).

Products named: Tevimbra

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $228,306
  • Ut Health San Antonio Mays Cancer Center $78,860
  • Icahn School of Medicine at Mount Sinai $27,742
  • Virginia Cancer Specialists, PC $10,000

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.